Leveraging Clinical Phenotyping to Optimize ADC Dosing & Mitigate Neurologic Toxicities for Improved Patient Safety
- Applying detailed clinical phenotyping and electrophysiologic assessment to distinguish between immune-mediated and direct payload-related neurologic toxicities, enabling more precise dose modification and management strategies
- Characterizing neuromuscular toxicity patterns across ADC-treated patients to identify early clinical signals and correlate toxicity phenotypes with dosing exposure, supporting safer therapeutic windows
- Developing a clinician-led framework to differentiate subtypes of peripheral neuropathy and neuromuscular junction disorders, informing mechanism-driven management approaches and guiding multidisciplinary decision-making for treatment continuation or discontinuation